Загрузка...
Interfering with interferons in inflammatory bowel disease
Early experience of fontolizumab, a humanised anti‐interferon γ antibody, in active Crohn's disease has shown that the drug caused a significant decrease in endoscopic severity scores and CRP and was reasonably well tolerated. Fontolizumab may be worthy of further clinical trials
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMJ Group
2006
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1856258/ https://ncbi.nlm.nih.gov/pubmed/16849343 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2005.090134 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|